Clinical trials: Esophageal Squamous Cell Carcinoma (ESCC), active
Esophageal Squamous Cell Carcinoma (ESCC)
Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study
This study is a prospective, randomized controlled, phase III multicenter trial. Its objectives are to explore the stratified application of consolidation immunotherapy after chemoimmunotherapy induction plus concurrent…
- Trial name
- NCT07246330
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer)
A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors
This is a Phase 1b, 2-part, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of [64Cu]Cu-AKY-2519 and/or [225Ac]Ac-AKY-2519, as well as the preliminary anti-tumor activity…
- Conditions
- NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer), ES-SCLC, Small Cell Lung Cancer Extensive Stage
- Trial name
- BActinium-2 (NCT07887971)
- Testing
- [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging)
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Aktis Oncology, Inc.
Esophageal Squamous Cell Carcinoma (ESCC), High-Grade Intraepithelial Neoplasia
Clinical Application of an AI-based Dissection Trajectory Prediction System (ADTPS) in Endoscopic Submucosal Dissection
In this prospective paired diagnostic study and single-center, randomized controlled trial, patients with early esophageal squamous neoplasia or high-grade intraepithelial neoplasia meeting the inclusion and exclusion criteria…
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC), High-Grade Intraepithelial Neoplasia, AI-Based Dissection Trajectory Prediction System
- Trial name
- NCT07757906
- Testing
- AI-based Dissection Trajectory Prediction System (ADTPS), Conventional ESD Procedure
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Qilu Hospital of Shandong University
Borderline Resectable Carcinoma, Unresectable Cancer
Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma
Esophageal cancer (EC) ranks among the leading malignant gastrointestinal tumors globally in terms of both incidence and mortality.
- Conditions
- Borderline Resectable Carcinoma, Unresectable Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Immune Checkpoint Inhibitor
- Trial name
- ILDR-03 (NCT07339488)
- Testing
- Intestinal Low Dose Radiotherapy-1Gy, PD-1/PD-L1 inhibitors, Chemotherapy
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Chuangzhen Chen
Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
This is a Phase 1/2a dose escalation and expansion study to determine the safety, tolerability, and preliminary clinical activity of 177LuBetaBart, a lutetium-labeled anti-B7-H3 monoclonal antibody, in patients with…
- Conditions
- Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer
- Trial name
- BetaBart (NCT07189871)
- Testing
- 177Lu-BetaBart, BetaBart + unlabeled BetaBart
- Where
- 5 sites in United States
- Volunteers
- 61 people
- Sponsor
- Radiopharm Theranostics, Ltd
NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC
- Trial name
- NCT07085091
- Testing
- ALX2004
- Where
- 12 sites in United States
- Volunteers
- 170 people
- Sponsor
- ALX Oncology Inc.
Esophageal Squamous Cell Carcinoma (ESCC), Cervical Squamous Cell Carcinoma
Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma
This multicenter retrospective-prospective cohort study evaluates predictive biomarker and tissue-pathology features for response to PD-1 inhibitor-based therapy in patients with squamous cell carcinoma (SCC).
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC), Cervical Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma, Head and Neck Squamous Carcinoma
- Trial name
- PB-PD1R-SCC (NCT07147361)
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophageal Squamous Cell Carcinoma (ESCC)
Risk of Esophageal Cancer Returning After Immunotherapy, Chemotherapy, and Surgery
This observational study aims to understand the risk of cancer returning after surgery in people with esophageal squamous cell carcinoma, a type of cancer of the food pipe.
- Trial name
- NCT07822906
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University Cancer Hospital & Institute
Esophageal Squamous Cell Carcinoma (ESCC)
Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Immunochemotherapy for Resectable Esophageal Cancer: A Target Trial Emulation Study
Esophageal squamous cell carcinoma (ESCC) is highly prevalent in China, with most patients presenting with locally advanced disease.
- Trial name
- TTE-ESCC (NCT07778056)
- Testing
- Radiotherapy, Platinum-based Chemotherapy, PD-1 Inhibitor
- Volunteers
- 400 people
- Sponsor
- Henan Cancer Hospital
HNSCC, ESCC
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.
- Conditions
- HNSCC, ESCC, Esophageal Adenocarcinoma, Gastric Adenocarcinoma
- Trial name
- NCT07182149
- Testing
- NRM-823
- Where
- 18 sites in United States
- Volunteers
- 150 people
- Sponsor
- Normunity AccelCo, Inc.
Esophageal Squamous Cell Carcinoma (ESCC)
Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal Cancer
This is a prospective, single-arm phase II clinical trial intended to investigate the efficacy of neoadjuvant CTLA-4 monoclonal antibody combined with PD-1 monoclonal antibody plus preoperative chemoradiotherapy for locally…
- Trial name
- NEOCRTE2601 (NCT07751055)
- Testing
- Ipilimumab (1mg/kg), Sinitilimab, Nab-paclitaxel + Cisplatin
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Sun Yat-sen University
Esophageal Squamous Cell Carcinoma (ESCC)
Early Response-guided Sequential Radiotherapy After Chemoimmunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Esophageal squamous cell carcinoma (ESCC) is a common and aggressive malignancy with poor prognosis, particularly in patients with locally advanced disease.
- Trial name
- Keystone006 (NCT07721103)
- Testing
- Neoadjuvant Chemoimmunotherapy (Tislelizumab Plus Paclitaxel and Cisplatin), Sequential Chemoradiotherapy
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Squamous Cell Carcinoma (ESCC)
Phase II Study of Induction Chemoimmunotherapy Followed by Radiotherapy and Organ Preservation in Resectable ESCC
This multicenter, prospective Phase II study investigates a response-adapted organ-preservation strategy in patients with resectable esophageal squamous cell carcinoma (ESCC).
- Trial name
- SCOPE (NCT07711470)
- Testing
- Sugemalimab and Chemotherapy, Nab-paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
ESCC, Gastric Adenocarcinoma
Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma
This is a single-arm, multi-center phase II study to evaluate the efficacy and safety of sacituzumab tirumotecan (Sac-TMT/SKB264) combined with tagitanlimab (KL-A167) as 2nd line therapy for recurrent or metastatic esophageal…
- Conditions
- ESCC, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma (ESCC)
- Trial name
- NCT07701681
- Testing
- Sacituzumab Tirumotecan + Tagitanlimab
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Sun Yat-sen University
Esophageal Squamous Cell Carcinoma (ESCC)
O-GlcNAcylation Induced HMGB1 Signalling
This study investigates how HMGB1 compartmentalisation and O-GlcNAcylation regulate inflammatory signalling, autophagy, and immune escape in cancer.
- Trial name
- NCT07702253
- Testing
- specimen collection
- Where
- Hong Kong
- Volunteers
- 120 people
- Sponsor
- Chinese University of Hong Kong
Esophageal Squamous Cell Carcinoma (ESCC)
PD-1 Inhibitors Combined With Local Therapy at Different Timings in Oligometastatic ESCC
Although immunotherapy combined with chemotherapy has become the first-line standard regimen for advanced esophageal squamous cell carcinoma (ESCC) and improved clinical outcomes in advanced patients, the prognosis of patients…
- Trial name
- ESO-shanghai31 (NCT07697859)
- Testing
- Two arms adopt local intervention administered at distinct timings.
- Where
- China
- Volunteers
- 354 people
- Sponsor
- Fudan University
Esophageal Squamous Cell Carcinoma (ESCC)
TDLN-Guided Lymphadenectomy After Neoadjuvant Immunochemotherapy for ESCC
This is a prospective, multicenter, observational cohort study of patients with esophageal squamous cell carcinoma who have received neoadjuvant immunochemotherapy and are scheduled to undergo curative esophagectomy with standard…
- Trial name
- NCT07697898
- Testing
- Curative Esophagectomy With Systematic Lymphadenectomy
- Volunteers
- 400 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer
Gastrointestinal (GI) cancers remain a major global health burden, largely due to the lack of effective and accessible early screening strategies.
- Conditions
- Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Esophageal Squamous Cell Carcinoma (ESCC)
- Trial name
- MiGIC (NCT07224750)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
ESCC
Integrated Cf-miRNA and Exosomal miRNA Signature for Early Detection of Esophageal Squamous Cell Carcinoma
Esophageal squamous cell carcinoma (ESCC) remains a highly lethal cancer worldwide, largely due to late diagnosis. Current screening methods such as upper endoscopy are invasive, operator-dependent, and limited in their ability…
- Trial name
- SYNERGY (NCT07266363)
- Testing
- Small RNA sequencing of exo- and cf-miRNAs, RT-qPCR quantification of cf- and exo-miRNAs (SYNERGY assay), PCR-based validation (SYNERGY assay)
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Esophageal Squamous Cell Carcinoma (ESCC)
Low-Dose Radiotherapy With Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
This study aims to evaluate the efficacy and safety of neoadjuvant low-dose radiotherapy combined with Retlirafusp alfa and chemotherapy in the treatment of resectable locally advanced esophageal squamous cell carcinoma.
- Trial name
- NCT07682376
- Testing
- Low-dose radiotherapy + Retlirafusp alfa + nab-paclitaxel + cisplatin/carboplatin, Retlirafusp alfa + nab-paclitaxel + cisplatin/carboplatin
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Harbin Medical University